Combination regimen of intravesical docetaxel, gemcitabine, and cisplatin in patients with BCG-unresponsive bladder cancer: clinical outcomes and genomic correlations
- 7 June 2025
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (10) , 594.e1-594.e7
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Mark Foundation For Cancer Research
- National Cancer Institute (P01 CA221757, R01 CA283068)
This publication has 28 references indexed in Scilit:
- Ultrafast one‐pass FASTQ data preprocessing, quality control, and deduplication using fastpiMeta, 2023
- Complex heatmap visualizationiMeta, 2022
- Bladder CancerJAMA, 2020
- Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non–muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysisEuropean Urology Oncology, 2020
- Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic TargetsEuropean Urology, 2017
- Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-AnalysisJournal of Urology, 2017
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, 2016
- Presentation and Diagnosis of Hypersensitivity to Platinum DrugsCurrent Allergy and Asthma Reports, 2015
- Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-GuérinUrologic Oncology: Seminars and Original Investigations, 2013
- Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic ReviewEuropean Urology, 2011